Protalix BioTherapeutics, Inc. Form 8-K	·.		
October 15, 2013			
UNITED STATES			
SECURITIES AND EXCH	ANGE COMMISSION		
Washington, D.C. 20549			
FORM 8-K			
CURRENT REPORT			
Pursuant to Section 13 or 1	5(d) of		
the Securities Exchange Act	t of 1934		
Date of Report (Date of Ear	liest Event Reported): Octob	per 14, 2013	
Protalix BioTherapeutics, I	nc.		
(Exact name of registrant a	s specified in its charter)		
Florida	001-33357	65-0643773	
(State or other jurisdiction	(Commission File Number)	(IRS Employer	
of incorporation)		Identification No.)	

Edgar Filing: Protalix BioTherapeutics, Inc. - Form 8-K

2 Snunit Street Science Park, POB 455 Carmiel, Israel (Address of principal executive offices)	20100 (Zip Code)			
Registrant's telephone number, including area code +972-4-988-9488				
(Former name or former address, if changed since last report.)				
** *	rm 8-K filing is intended to simultaneously satisfy the filing obligation of rovisions (see General Instruction A.2. below):			
"Written communications pursuant to Rule	e 425 under the Securities Act (17 CFR 230.425)			
"Soliciting material pursuant to Rule 14a-1	2 under the Exchange Act (17 CFR 240.14a-12)			
"Pre-commencement communications purs	suant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))			
"Pre-commencement communications purs	suant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))			

Item 8.01. Other Events

On October 14, 2013, Protalix BioTherapeutics, Inc. issued a press release announcing initial positive results from its phase I clinical trial of oral glucocerebrosidase (GCD), or Oral GCD (PRX-112), in patients with Gaucher disease. A copy of the press release is filed as Exhibit 99.1.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits

99.1 Press release dated October 14, 2013.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PROTALIX BIOTHERAPEUTICS, INC.

Date: October 15, 2013 By: /s/ David Aviezer

Name: David Aviezer, Ph.D.

Title: President and

Chief Executive Officer

3